Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists by Mosinska, Paula et al.
171
Future Treatment of Constipation-associated 
Disorders: Role of Relamorelin and Other Ghrelin 
Receptor Agonists 
Paula Mosińska,1* Hubert Zatorski,1 Martin Storr,2 and Jakub Fichna1
1Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland; and 2Center of Endoscopy, Starnberg, Germany 
and Walter-Brendel-Centre, Ludwig-Maximilians University Munich, Munich, Germany
There is an unmet need for effective pharmacological therapies for constipation, a symptom that significantly deteriorates patients’ 
quality of life and impacts health care. Ghrelin is an endogenous ligand for the growth hormone secretagogue receptor and has been 
shown to exert prokinetic effects on gastrointestinal (GI) motility via the vagus and pelvic nerves. The pharmacological potential of 
ghrelin is hampered by its short half-life. Ghrelin receptor (GRLN-R) agonists with enhanced pharmacokinetics were thus developed. 
Centrally penetrant GRLN-R agonists stimulate defecation and improve impaired lower GI transit in animals and humans. This review 
summarizes the current knowledge on relamorelin, a potent ghrelin mimetic, and other GRLN-R analogs which are in preclinical or 
clinical stages of development for the management of disorders with underlying GI hypomotility, like constipation. 
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Introduction  
Constipation as a chronic digestive condition significantly dete-
riorates patients’ quality of life. It is much more common amongst 
women compared to men and the probability of the occurrence of 
constipation increases with age. The worldwide prevalence rates of 
physician-confirmed or patient self-reported constipation ranges 
from 12.3% to 25.1%.1-5 In clinical practice the separation be-
tween chronic idiopathic constipation (chronic constipation [CC] 
of undefined pathophysiology that does not have any organic or 
physiological cause), constipation-predominant irritable bowel syn-
drome (IBS-C), and CC (gastrointestinal [GI] disorder caused by 
normal colon transit, slow colon transit or dyssynergic defecation) 
is still difficult.6 Although the diagnosis of IBS-C is based on the 
Rome IV criteria, the diagnosis of CC is made by exclusion of other 
conditions without thorough investigation. The Bristol stool scale 
serves as an universal tool for the determination of stool consistency. 
Regardless of the final diagnosis, each condition is characterized 
by feeble or absent colonic propagated activity. A great number of 
drugs tested in preclinical in vivo studies for the treatment of IBS-
C are simultaneously verified also as a potential option for CC or 
chronic idiopathic constipation. Currently, conventional treatment 
options used to improve constipation-related symptoms like ab-
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dominal pain, straining, and hard stools, are of limited efficacy and 
usually judged as unsatisfactory.7,8 
Ghrelin is a 28-amino acid peptide produced mainly in the P/
D1 and X/A-like cells of the oxyntic mucosa of the stomach and 
in the hypothalamus. Importantly, the X/A-like endocrine cells are 
solely responsible for 80-90% secretion of ghrelin. The peptide has 
recently been described as a natural ligand for the ghrelin receptor 
(GRLN-R), also known as the growth hormone secretagogue-
1α receptor. GRLN-Rs are expressed in the central nervous 
system and in peripheral tissues and are involved in numerous 
functions9-17; the main central and peripheral functions are sum-
marized in Figure. The activation of GRLN-R modulates multiple 
intracellular signaling pathways and exhibits different endocrine 
and non-endocrine effects.18 While administered either peripherally 
or centrally, ghrelin stimulates food intake through GRLN-Rs on 
vagal afferents or via the bloodstream.15,19 Moreover, by targeting 
hypothalamic neurons and the sympathetic nervous system, ghrelin 
regulates lipid-metabolizing enzymes in adipocytes.20 Ghrelin also 
interacts with the reproductive, cardiovascular and immune sys-
tems.21-25 Currently, ghrelin is considered as a possible option for the 
treatment of conditions with impaired gastric motility, reduced GI 
motility and altered energy balance.
Since the discovery of ghrelin in 1999,26 its usefulness was thor-
oughly evaluated in the treatment of upper GI diseases, especially 
gastroparesis. More recent studies in animals and humans report 
a prokinetic activity in the lower GI-tract with ghrelin potentially 
being helpful for the treatment of lower GI diseases, such as CC or 
postoperative ileus (POI).27,28 Although the expression of ghrelin 
is relatively low in the small and large intestines, when compared to 
the stomach, the GRLN-Rs are in turn dispersed throughout the 
GI tract and a high mRNA expression was reported especially in 
the colon of humans and rodents. In more detail this high expres-
sion was reported on fibers and cell bodies of the enteric nervous 
system in rats, and in the myenteric neurons of the guinea pig il-
eum.20,29,30 
Numerous studies in rodents demonstrate an enhanced motor 
activity in the duodenum following administration of exogenous 
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GRLN-Rs by centrally penetrant GRLN-R agonists in the lumbo-
sacral spinal cord initiates and enhances propulsive contractile activ-
ity in the distal colon.33,34
Ghrelin induces contractile activity in the GI tract, but the short 
half-life and plasma instability of ghrelin impairs the usefulness.35 
Hence, small molecule–GRLN-R agonists with prolonged recep-
tor activity currently represent an attractive therapeutic option for 
the management of lower GI tract motility disorders. In this review 
we summarize the latest preclinical and clinical studies evaluating 
the potential of relamorelin and other GRLN-R agonists in im-
proving delayed colonic transit.
Relamorelin  
Relamorelin (RM-131) is a pentapeptide synthetic ghrelin 
analog that stimulates the release of growth hormone in a compa-
rable manner as natural ghrelin. It binds to the GRLN-R with 
approximately 3-fold higher affinity to ghrelin receptors than native 
ghrelin.36,37 Moreover, RM-131 exerts improved stability, greater 
potency, and longer plasma half-life.36,38 RM-131 may be used in 
the treatment of gastroparesis, since in gastroparesis RM-131 ac-
celerates gastric emptying without causing severe adverse effects. 
The most common side effects in RM-131 treated patients are 
dizziness, fatigue, abdominal pain/cramping, hunger, feeling cold, 
and muscular weakness.39 Considering the prokinetic properties of 
RM-131 on the upper GI tract, many studies put also an interest 
on its effect in the treatment of the lower GI motility disorders. A 
study by Van der Ploeg et al36 showed that RM-131 reversed the 
reduction of gastric emptying and was up to 100-fold more potent 
than ghrelin or other ghrelin mimetics in rat models of POI and 
morphine-induced ileus. Besides its effect on gastric emptying, oral 
administration of RM-131 also enhanced GI transit in the proximal 
and middle part of the small intestine. Moreover, in a rat model of 
TNBS-induced GI inflammation the administration of a single 
dose of RM-131 (5 or 50 nmol/mouse) increased the rats’ survival 
and reduced signs of macroscopic colonic inflammation, suggesting 
that RM-131 also mediates an anti-inflammatory response.36 
Translated into humans, in a randomized, double-blinded, pla-
cebo-controlled trial, RM-131 administered subcutaneously for 14 
days at the dose of 100 µg/day significantly reduced the symptoms 
of constipation in females with CC who met the Rome III criteria.37 
RM-131 significantly enhanced bowel function by increasing the 
number of spontaneous bowel movements and accelerated GI and 
colonic transit. Importantly, the positive response was observed im-
mediately after the first administration of RM-131. The primary 
clinical endpoint for the function of the intestine was stool consis-
tency (assessment based on the Bristol stool scale), and the second-
ary endpoints included stool frequency, time to first bowel move-
ment and completeness of evacuation. The ghrelin agonist was well-
tolerated. Some patients experienced tiredness, enhanced appetite 
and headache. 
More recently, Acosta et al40 characterized the acute motor 
effects of RM-131 in patients with CC using colonic barostat 
and multilumen manometry. In a placebo-controlled, single dose, 
double blind, randomized study Acosta et al41 showed that a sub-
cutaneous injection of isotonic RM-131 solution significantly in-
creased colonic propagated contractions (PCs) and in consequence 
accelerated overall colonic motor activity. No differences in the 
number of high amplitude propagated contractions (HAPCs) and 
in sensation thresholds for gas and pain were observed between the 
RM-131-treated and control groups. However, the administra-
tion of RM-131 resulted in an increased frequency of pre-meal 
PCs and a significantly higher number of postprandial PCs, when 
compared to the placebo group. The observed activity in the colon 
is comparable to the effects seen following a treatment with other 
colonic prokinetics such as prucalopride, or other serotonin receptor 
agonists or neostigmine; however, in contrast to the above men-
tioned drugs RM-131 exhibits a delayed effect (24-36 hour post-
administration) on the colonic motility.42-44 To further characterize 
the effects reported in the human colon the same group of authors 
evaluated the clinical efficacy of RM-131 in patients with con-
firmed CC. Similarly to their first clinical trial, the propulsive effects 
of RM-131 were confirmed, and the trial added that the duration 
of RM-131 is long-lasting with RM-131 activity being reported 
for a minimum of 1 hour.41
Another study interested in the underlying mechanisms dem-
onstrated that RM-131 hyperpolarizes the resting membrane 
potential of mouse and human colon circular smooth muscle cells 
and decreases colonic intraluminal pressure.45 RM-131 exerted no 
effect on either fast inhibitory junction potentials or slow inhibitory 
junction potentials. The concurrent effect of RM-131 in decreasing 
colonic intraluminal pressure and increasing upper GI contractility 
may widen its application towards functional GI disorders.46
Very recently, a single-center, placebo-controlled, double-blind-
ed study was initiated in patients with CC who received a single 
injection of 100 µg of RM-131. The primary endpoint included 
the effect of RM-131 on postprandial HAPC within one hour. No 
results have been published yet; however, the trial may be followed 
under the Clinical Trial registration number (ClinicalTrals gov. 
Identifier: NCT 02137642). 
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Other Ghrelin Receptor Agonists  
The defecation center in the lumbo-sacral spinal cord con-
stitutes an investigational target for the treatment of constipation. 
Small-molecules, such as urimorelin, capromorelin, EX-1314, 
CP464709, GSK894281, and ipamorelin stimulate this center and 
are thought to ameliorate bowel movement in animals. A small 
number of clinical trials have been performed so far (Table 1). 
Ulimorelin (TZP-101)
Ulimorelin is a macrocyclic peptidomimetic agent widely inves-
tigated in the management of diabetic gastroparesis (ClinicalTrials.
gov Identifier: NCT00612014) and POI (ClinicalTrials.gov Iden-
tifier: NCT01710982) but more recently it is also in the spotlight 
in the treatment of constipation. Pustovit et al47 reported a dose-de-
pendent increase in the numbers and amplitudes of phasic pressure 
waves in the colorectum in anesthetized rats following intravenous 
administration of ulimorelin. Interestingly, when delivered directly 
to the lumbo-sacral spinal cord, ulimorelin increased propulsive 
activity more significantly compared to intravenous injections. The 
effect of ulimorelin was blocked by both the nicotinic receptor an-
tagonist (hexamethonium) and GRLN-R antagonist, indicating 
that the responses were dependent on sustained activation of neuro-
nal pathways. Yet, there are no clinical trials evaluating the effect of 
this GRLN-R agonist in patients with constipation. 
Capromorelin
In a rat model of low fiber-induced constipation, capromorelin 
stimulates colonic motility and improves defecation patterns.48 
Ferens et al34 reported that when applied intravenously at a dose 
of 4 mg/kg, capromorelin elicits contractions in the colon of spinal 
cord-injured rats resulting in spontaneous defecations. Though, the 
safety profile, tolerability and pharmacokinetic properties of capro-
morelin was assessed in spinal cord-injured patients with constipa-
tion,49 the currently available data is not detailed enough to support 
a possible clinical application of capromorelin in the management 
of constipation. There are no ongoing studies registered in Clini-
calTrials.gov, suggesting that its development may no longer being 
pursued.
EX-1314
Oral administration of the small-molecule EX-1314 (Elixir) at 
a dose of 300 mg/kg significantly enhanced small intestinal transit 
in mice, when compared to vehicle-treated controls.50 The adminis-
tration of EX-1314 in fed animals resulted in a 2-fold greater fecal 
output compared to the control group. In contrast, in fasted animals 
EX-1314 did not show significant differences in fecal pellet out-
puts. Thus a stimulation of food intake by the synthetic GRLN-R 
agonist may be needed to facilitate the prokinetic effects of GRLN-
R agonists. None of the groups showed signs of diarrhea or other 
side effects. 
GRLN-R has prokinetic effects on morphine-induced hypo-
Table 1. Ghrelin Receptor Agonists Under Investigation in Preclinical Animal Studies
Generic name
Route of  
administration
Effect Animal model Reference No.
Capromorelin iv, po Similar observations in stimulating colorectal 
propulsion observed in treated and control 
group
Diet-induced constipation 48
CP464709 iv, intrathecal Increased fecal pellet output; stimulation of  
defecation
Control rats 33
GSK894281 po Dose-related increase in fecal pellet output Control rats 47
EX-1314 (Elixir) po Increased SIT Mice with opioid-induced ileus; 
opiate-induced GI dysmotility
50
Ipamorelin iv Increases cumulative fecal pellet output Rats with POI 51
TZP-101 (Ulimorelin) iv Increased colonic transit and fecal pellet output Rats with POI 28
iv Increased the colorectal propulsive activity and 
fecal pellet output
Control rats 49
iv Increased gastric emptying and SIT Rats with POI; rats with  
morphine-induced dysmotility
36
iv, intravenous; po, per os; SIT, increased small intestinal transit; GI, gastrointestinal; POI, postoperative ileus.
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motility. EX-1314 reversed the action of morphine and restored the 
small GI transit in mice to levels observed for controls.50
CP464709
CP46709 is centrally penetrant following subcutaneous or in-
travenous application and improves colonic motility and defecation 
patterns in rats.33,52 When injected subcutaneously at a dose of 5 or 
10 mg/kg, CP464709 caused a substantial stimulation of defecation 
in the first hour following administration, which represented four-
fold increased defecation rates compared to vehicle-treated animals. 
This effect diminished at greater doses (> 20 mg/kg) suggesting a 
possible dose-dependent desensitization of receptors.33,52
Consistently, rats injected with CP46470 intravenously dem-
onstrated strong propulsive contractions in the colorectum, without 
changing the baseline motility of the colon. It is thus possible that 
the GRLN-R agonist activates the defecation center of the L6-
S2 lumbo-sacral region of the spinal cord, stimulating autonomic 
nerve input and thus promoting colorectal motility, without direct 
effects on colonic smooth muscle cells.33,52 This effect was observed 
in conscious as well as in anesthetized rats, and was manifested by a 
substantial stimulation of defecation without affecting small intesti-
nal motility.
GSK894281
GSK894281 is another small-molecule that when administered 
orally to rats enhanced the fecal output nearly four times, compared 
to controls.46 The pharmacokinetic evaluation of GSK894281 
showed high potency towards GRLN-Rs, with a half-life up to 
5.5 hours, and a bioavailability of 75% following oral administra-
tion.46 The peak of fecal expulsion was observed during the first 30 
minutes after GSK894281 administration (10 mg/kg) suggesting 
a very fast onset of action. There is no loss of action since even after 
chronic administration for 8 consecutive days (daily dose of 10 mg/
kg), GSK894281 maintained a powerful prokinetic effect. The fecal 
output was approximately 16% greater until the 6th control day af-
ter the treatment, compared with the days before the study. A dose-
dependent increase in fecal output was observed at all time points. 
It has to be noted that during the period of 8 days rats gained 25% 
body weight, an observation that mimics the known effects of ghre-
lin. After discontinuation of GRLN-R agonist, the weight returned 
to original values. Similarly to other GRLN-Rs agonists, the effects 
of GSK894281 were probably induced by stimulating receptors in 
the lumbo-sacral spinal cord.
Ipamorelin
Limited data is available on possible effects of ipamorelin in 
constipation-related disorders; however, there are in vivo studies 
and clinical trials assessing its capabilities in the treatment of POI. 
Repetitive intravenous administration of ipamorelin (0.1 mg/kg 
or 1 mg/kg) accelerated colonic transit by shortening the time to the 
first bowel movement and significantly increased food intake and 
body weight in a rat model of POI. Single infusions of ipamorelin 
showed an increase in fecal pellet output.53 
Recently, a multicenter double-blinded, placebo-controlled trial 
evaluated the safety of ipamorelin on patients with POI following 
abdominal surgery (ClinicalTrial.gov Identifier: NCT1280344). 
The treatment with ipamorelin was well tolerated but there were no 
significant differences in measurable motility parameter between 
placebo and treated groups. The most common treatment-associat-
ed adverse events were consistent with patients having undergone 
recent bowel surgery ie, nausea, vomiting, and dyspepsia, and may 
therefore not be associated with ipamorelin. However, the time to 
recovery of GI function was shorter in ipamorelin-treated group 
than in placebo. Helsinn Therapeutics, Inc is currently develop-
ing ipamorelin in a Phase 2b clinical trial for the future treatment 
of postoperative bowel dysmotility (ClinicalTrial.gov Identifier: 
NCT00672074). 
Limitations and Directions for Future  
Research of Ghrelin Receptor Agonist  
The majority of studies mentioned in this paper support the 
notion that the small-molecule ghrelin and GRLN-R agonists 
may offer a well-integrated therapeutic option for the manage-
ment of various hypomotility-related disorders, such as CC and 
POI (Table 2). 
Several consistent results from both animal studies and clinical 
trials, provide strong evidence for powerful and sustainable effects 
of RM-131 in improving bowel function and increasing intestinal 
transit, without causing severe side effects. However, despite hold-
ing a great promise, further studies are still needed to fully establish 
the chronic effects of RM-131 on colonic motility.
As shown by the studies described herein, the effect of GRLN-
R agonists on lower GI transit was assessed mainly acutely in vitro 
and in vivo in the colon. Although most of the investigations fol-
lowed well-designed protocols, and the results indicated pro-stimu-
latory actions of each agent on the intestines, none of available stud-
ies assessed the effects of a real long-term treatment. Importantly, 
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we should keep in mind that the tested agonists usually desensitize 
very easily, and thus may not sustain long enough to produce a de-
sirable effect in a chronic mode of application. 
In line, as mentioned before some GRLN-R agonists prompt 
colonic motility only after being administered intravenously or sub-
cutaneously. If this beneficial effect of GRLN-R agonists may be 
maintained also after oral administration, these compounds may be 
useful in the future management of constipation or to ease cleansing 
the bowel before colonoscopy. At present, only GSK894281, given 
orally to rats, have elicited such effects. Presently, GSK894281 is the 
most promising compound that should be considered for further 
evaluation in clinical trials, especially being one of the very few that 
can cross the blood-brain barrier. 
While improving the pharmacokinetic properties, it is advisable 
to consider not only the bioavailability of agents, but also the other 
effects of ghrelin and GRLN-Rs agonists on appetite, food intake 
and body weight, since these effects may limit the clinical long term 
usefulness. For example, EX-1314, which is currently under evalu-
ation in preclinical in vivo studies, and also relamorelin and ipamo-
relin which have recently completed Phase 2 clinical trials, were 
associated with stimulation of GRLN-Rs in the appetite centers of 
the brain and increased appetite, thus their long-lasting use may be 
limited, especially when patient experience other comorbidities such 
as metabolic syndrome or type II diabetes. These aspects urgently 
need further attention, especially in the presently ongoing clinical 
trials.
In summary, considering the improvement in defecation pat-
terns in animals and humans following administrations of GRLN-
R agonists, these agents may herald a new class of anti-constipation 
drugs. Additional clinical trials are necessary to further characterize 
and develop the promising clinical effects.
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